Inactive Instrument

News Stellar Biotechnologies Inc Nasdaq

Equities

Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	11/05	CI
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	12/04	AQ
Edesa Biotech to Participate in Barclays Global Healthcare Conference	08/03	AQ
Top Premarket Gainers	05/03	MT
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	10/02	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	16/12	CI
Top Premarket Decliners	13/12	MT
HC Wainwright Adjusts Price Target on Edesa Biotech to $21 From $70, Keeps Buy Rating	29/11	MT
Top Premarket Gainers	22/11	MT
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	21/11	CI
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug	26/23/26	AQ
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/23/25	CI
Top Premarket Decliners	13/23/13	MT
Sector Update: Health Care Stocks Decline in Late Afternoon	13/23/13	MT
Sector Update: Health Care	13/23/13	MT
Top Midday Gainers	12/23/12	MT
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/23/12	CI
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/23/10	MT
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate	29/23/29	AQ
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	28/23/28	CI

No results for this search